Fig. 3: Characterization of IDH1 R132H/D279N. | npj Precision Oncology

Fig. 3: Characterization of IDH1 R132H/D279N.

From: Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

Fig. 3

a Immunoblot analysis of IDH1 expression in TF-1 cells infected with lentivirus expressing the indicated IDH1 variants and treated with vehicle-control (DMSO), 500 nM ivosidenib (IVO), or 500 nM LY3410738 (LY), as indicated. b, c Quantification of (R)-2HG (b) and fold-change in (R)-2HG (c) in the TF-1 cell lines shown in a, as indicated. Shown are mean values (±SD) of duplicate experiments. d, e Proliferation under cytokine-poor conditions (d) and fold-change in day 15 cell counts (e) of the TF-1 cells shown in (a) The mean (±SD) cell counts of three replicates is shown. f Fold-change in intracellular (R)-2HG in TF-1 cells expressing IDH1 R132H (left) or IDH1 R132H/D279N (right) treated overnight with the indicated concentrations of LY3410738. Shown are mean values (±SD) of duplicate experiments. In all cases, representative results from at least two independent experiments are shown.

Back to article page